Peroxidase and CYP-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia

Abstract

peroxidases and cytochroem P450 activate anticancer drug ellipticine to reactive species binding to DNA in vitro. This mechanism can explain the anticancer specificity of this agent.